Suppr超能文献

载 mRNA 的脂质纳米颗粒增强型 CAR-巨噬细胞工程用于清除脓毒症小鼠模型中的多药耐药菌。

mRNA-Laden Lipid-Nanoparticle-Enabled CAR-Macrophage Engineering for the Eradication of Multidrug-Resistant Bacteria in a Sepsis Mouse Model.

机构信息

NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Cultural West Road, Jinan, Shandong Province 250012, China.

Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 Cultural West Road, Jinan, Shandong Province 250012, China.

出版信息

ACS Nano. 2024 Jan 23;18(3):2261-2278. doi: 10.1021/acsnano.3c10109. Epub 2024 Jan 11.

Abstract

Sepsis, which is the most severe clinical manifestation of acute infection and has a mortality rate higher than that of cancer, represents a significant global public health burden. Persistent methicillin-resistant (MRSA) infection and further host immune paralysis are the leading causes of sepsis-associated death, but limited clinical interventions that target sepsis have failed to effectively restore immune homeostasis to enable complete eradication of MRSA. To restimulate anti-MRSA innate immunity, we developed CRV peptide-modified lipid nanoparticles (CRV/LNP-RNAs) for transient programming of macrophages (MΦs). The CRV/LNP-RNAs enabled the delivery of MRSA-targeted chimeric antigen receptor (CAR) mRNA (SasA-CAR mRNA) and CASP11 (a key MRSA intracellular evasion target) siRNA to MΦs , yielding CAR-MΦs with boosted bactericidal potency. Specifically, our results demonstrated that the engineered MΦs could efficiently phagocytose and digest MRSA intracellularly, preventing immune evasion by the "superbug" MRSA. Our findings highlight the potential of nanoparticle-enabled generation of CAR-MΦs as a therapeutic platform for multidrug-resistant (MDR) bacterial infections and should be confirmed in clinical trials.

摘要

脓毒症是急性感染最严重的临床表现,其死亡率高于癌症,是全球重大公共卫生负担。持续的耐甲氧西林金黄色葡萄球菌(MRSA)感染和进一步的宿主免疫麻痹是导致脓毒症相关死亡的主要原因,但针对脓毒症的有限临床干预措施未能有效恢复免疫平衡,从而无法彻底消除 MRSA。为了重新激发抗 MRSA 固有免疫,我们开发了 CRV 肽修饰的脂质纳米颗粒(CRV/LNP-RNAs),用于短暂编程巨噬细胞(MΦs)。CRV/LNP-RNAs 能够将靶向 MRSA 的嵌合抗原受体(CAR)mRNA(SasA-CAR mRNA)和 CASP11(MRSA 细胞内逃逸的关键靶标)siRNA 递送至 MΦs,产生增强杀菌效力的 CAR-MΦs。具体而言,我们的结果表明,工程化的 MΦs 可以有效吞噬和消化细胞内的 MRSA,防止“超级细菌”MRSA 的免疫逃逸。我们的研究结果强调了纳米颗粒介导的 CAR-MΦs 作为治疗多药耐药(MDR)细菌感染的治疗平台的潜力,应该在临床试验中得到证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验